Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3 Global Registrational Trial of Bemarituzumab
AMENDED FROM SOURCE - Blue Sky Uranium Increases and Closes 2nd and Final Tranche of the Oversubscribed Non-Brokered Private Placement
